Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors

Yuji Ikari, Yuya Matsue, Sho Torii, Misaki Hasegawa, Kazuki Aihara, Shunsuke Kuroda, Takahide Sano, Takeshi Kitai, Taishi Yonetsu, Shun Kohsaka, Takuya Kishi, Issei Komuro, Ken Ichi Hirata, Koichi Node, Shingo Matsumoto

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Cardiovascular diseases and/or risk factors (CVDRF) have been reported as risk factors for severe coronavirus disease 2019 (COVID-19). Methods and Results: In total, we selected 693 patients with CVDRF from the CLAVIS-COVID database of 1,518 cases in Japan. The mean age was 68 years (35% females). Statin use was reported by 31% patients at admission. Statin users exhibited lower incidence of extracorporeal membrane oxygenation (ECMO) insertion (1.4% vs. 4.6%, odds ratio [OR]: 0.295, P=0.037) and septic shock (1.4% vs. 6.5%, OR: 0.205, P=0.004) despite having more comorbidities such as diabetes mellitus. Conclusions: This study suggests the potential benefits of statins use against COVID-19.

Original languageEnglish
Pages (from-to)939-943
Number of pages5
JournalCirculation Journal
Volume85
Issue number6
DOIs
Publication statusPublished - 2021

Keywords

  • Cardiovascular risk factors
  • Coronavirus disease 2019 (COVID-19)
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Association between statin use prior to admission and lower coronavirus disease 2019 (COVID-19) severity in patients with cardiovascular disease or risk factors'. Together they form a unique fingerprint.

Cite this